Eye pain, blurred vision, or halos after a dose — notify the provider now; possible acute angle-closure glaucoma.
Before you read
Test yourself first: 3 questions
Question 1 of 3
A client with COPD is prescribed ipratropium by inhalation. The nurse explains this medication is used to achieve which effect?
Answer: A. Ipratropium is an inhaled anticholinergic (antimuscarinic) bronchodilator that blocks vagally mediated bronchoconstriction, producing bronchodilation for maintenance therapy in COPD. It is not a rescue medication for acute attacks, does not reduce systemic inflammation, and is not an expectorant.
Question 2 of 3
A client is prescribed ipratropium, an inhaled anticholinergic bronchodilator. The nurse should monitor for which expected side effect of this medication?
Answer: A. Ipratropium is an anticholinergic (antimuscarinic) bronchodilator. Its anticholinergic action commonly produces dry mouth. Other anticholinergic effects can include throat irritation and, rarely, urinary retention or blurred vision. It does not typically cause bradycardia, increased salivation, or diarrhea.
Question 3 of 3
A nurse is reviewing new prescriptions for a client with COPD. Which medication, if prescribed, should the nurse question due to its anticholinergic effects in a client with a history of narrow-angle glaucoma and benign prostatic hyperplasia?
Answer: B. Inhaled anticholinergics such as ipratropium and tiotropium are used cautiously in clients with narrow-angle glaucoma and benign prostatic hyperplasia because anticholinergic effects can raise intraocular pressure and worsen urinary retention. The nurse should question the anticholinergic. Albuterol, fluticasone, and montelukast do not carry these specific anticholinergic precautions.
Keep the streak going with more questions like these, each with a full rationale.
What is ipratropium?
It blocks acetylcholine in the airways, which relaxes airway smooth muscle and reduces secretions. It is used mainly for COPD maintenance and as an add-on in asthma exacerbations, often combined with albuterol (DuoNeb, Combivent). Its onset is slower than albuterol's, so it is not a first-line rescue drug. The nurse watches for anticholinergic effects such as dry mouth, blurred vision, and eye pain, and uses caution in glaucoma and urinary retention.
Key points to remember
- Class: anticholinergic bronchodilator (SAMA) that opens airways and dries secretions.
- Onset is slower than a SABA such as albuterol, so it is not the first rescue drug for acute bronchospasm.
- Main use: COPD maintenance; it may be added in asthma exacerbations.
- Combined with albuterol (DuoNeb, Combivent), the bronchodilator effect is greater.
- Side effects: dry mouth, cough, unpleasant taste, and blurred vision.
- Use caution in glaucoma and in urinary retention from BPH; mist in the eyes can trigger acute angle-closure glaucoma.
- Older MDI formulations contained lecithin, so ask about peanut or soy allergy before using those products.
Signs & symptoms
- Dry mouth, cough, blurred vision
- Slow onset → not rescue 1st-line
Nursing priorities
- Assess breathing, lung sounds, and work of breathing before and after each dose, because the response shows whether bronchodilation is adequate.
- Ask about peanut or soy allergy before using an older MDI product, because those formulations contained lecithin.
- Screen for glaucoma and for BPH or urinary retention, because anticholinergic effects can worsen both.
- Teach correct inhaler or nebulizer technique and keep the mist away from the eyes, because mist in the eyes can trigger angle-closure glaucoma.
- When albuterol is ordered as a separate treatment, give the two drugs in the ordered sequence and monitor for tachycardia, because albuterol can cause a fast, pounding heartbeat.
Worked example
- Cue: An older adult with COPD and BPH receives ipratropium–albuterol by nebulizer through a loose-fitting mask. Afterward they report eye pain and halos around lights.
- Meaning: Mist reached the eyes; this may be acute angle-closure glaucoma, an anticholinergic effect.
- Priority action: Notify the provider now, hold further doses until the eye is evaluated, and plan a mouthpiece or better-fitting mask.
- Evaluation: The eye is evaluated promptly, breathing stays controlled, and the client voids without difficulty.
Patient teaching
- This medicine controls your breathing day to day. It works more slowly than your rescue inhaler, so use the rescue inhaler for sudden attacks.
- Keep the mist out of your eyes, and use the mouthpiece or mask correctly. Call right away for eye pain or blurry vision with halos.
- For dry mouth, rinse your mouth, sip water, chew gum, or suck on hard candy.
Common mistakes
- Choosing ipratropium as the rescue drug for acute bronchospasm; albuterol acts faster.
- Skipping the peanut or soy allergy question with older MDI products.
- Missing the anticholinergic cautions: glaucoma and urinary retention from BPH.
- Brushing off eye pain or halos after a nebulizer treatment given through a loose mask.
Red flags: report now
- Eye pain, blurred vision, or halos after a dose — notify the provider now; possible acute angle-closure glaucoma.
- Worsening dyspnea or wheezing right after a dose (paradoxical bronchospasm) — hold further doses and notify the provider now.
- Acute bronchospasm being treated with ipratropium alone — notify the provider; a faster-acting rescue bronchodilator is needed.
- Difficulty urinating in a client with BPH — report possible urinary retention.
References
Clinical references for this topic
